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Background: Ovarian cancer is the most lethal gynecologic cancer in the United States. 
High-grade serous ovarian cancer (HGSOC) accounts for 70%-90% of all ovarian cancer death. 
It is crucial to identify efficient prognostic biomarkers to inform treatment decision making. 
Method: Tissue microarrays and clinical data were obtained from patients diagnosed 
with invasive HGSOC enrolled in studies participating in the Ovarian Tumor Tissue Analysis 
consortium. Cox proportional hazard regression analysis (CoxPHR) with lasso penalty was 
performed to select the most important variables related to overall survival (OS) from clinical 
prognostic data and 9 immunohistochemistry (IHC) biomarkers of interest, MyD88, TLR4, 
FOLT1, CD8+ tumor-infiltrating lymphocytes (CD8+ TILs), p16, PTEN, progesterone receptor 
(PR), estrogen receptor (ER) and androgen receptor (AR) using a training set of 254 patients 
with all 9 IHC data. The external validation was conducted using the test set of 1563 patients 
with data of the selected IHC biomarker by lasso. Hazard ratios (HRs) and 95% confidence 
intervals (CIs) of the selected variables were estimated from the CoxPHR. Kaplan-Meier curves 
were used to visually compare survival across the selected variables. A nomogram was generated 
to estimate the 2-year and 3-year survival.  
Results: The median OS time of the training set was 5.04 years (95% CI 4.36- 5.99 
years). The selected variables from CoxPHR with lasso penalty include age at diagnosis, stage, 
v 
debulking status, AR, TLR4, CD8+ TILs, and p16. The median OS of the test set is 3.41 years 
(95% CI 3.21-3.63 years). The cases in the test set are at a more advanced stage. C-index from 
the prediction model fitting in the test set is 0.63. In the prediction model, CD8+ is inversely 
associated with the hazard of death (P for trend = 0.0011). 
Conclusion: The CoxPHR model with lasso penalty identifies four IHC biomarkers, AR, 
TLR4, CD8+, and p16, along with age at diagnosis, tumor stage, and debulking status, as 
prognostic factors for HGSOC survival. Further study containing more IHC candidates and 
clinical variables, such as chemotherapy response, and using continuous IHC scores should be 
performed to increase the accuracy of the prediction model for HGSOC survival.  
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1.0 Background 
1.1 High-grade serous ovarian cancer 
1.1.1  Statistics of HGSOC 
Ovarian cancer is a heavy burden in the United States. About 13,940 women will die from 
ovarian cancer in 2020 in the U.S, according to the American Cancer Society, which is more than 
any other gynecologic cancer (American Cancer Society, 2020; Olsen et al., 2013). Epithelial 
ovary cancer (EOC) accounts for nearly 90% of malignant ovarian cancer (American Cancer 
Society, 2020). High-grade serous ovarian cancer (HGSOC), accounting for more than 60% of 
EOC and 70%-90% of all ovarian cancer deaths, is the most deadly histologic subtype of EOC 
(Bowtell et al., 2015; Gurung, Hung, Morin, & Gilks, 2013; Lauren C. Peres et al., 2019).  
There are two systems for staging ovarian cancer, the International Federation of 
Gynecology and Obstetrics system and the American Joint Committee on Cancer TNM staging 
system. These systems are the same in that they both use three factors to stage cancer, including 
the extent of the tumor, the spread to nearby lymph nodes, the spread to distant sites. Higher 
numbers indicate more advanced cancer. The Surveillance, Epidemiology, and End Results 
registry (SEER) program of the National Cancer Institute (NCI) use a simplified approach to stage 
ovarian cancer as localized (roughly Stage I disease), regional (encompassing Stage II and III 
disease) and distant (Stage IV disease) (National Cancer Institute, March 9, 2015). HGSOC 
primarily arises from the fallopian tube and then spread to the ovary (J. Kim et al., 2018; Kurman 
& Shih Ie, 2010; Salvador et al., 2009). More than 75% of HGSOC cases are diagnosed at an 
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advanced stage (stage III/IV) (L. C. Peres et al., 2019; Seidman, Zhao, & Yemelyanova, 2011). 
According to the SEER registry data, the prognosis for patients diagnosed in the advanced stages 
is very poor (Baldwin et al., 2012; L. C. Peres et al., 2019). The data from 40,692 EOC patients in 
SEER from 1995-2007 indicates that the 5-year survival of EOC is 17% for stage IV, and the 10-
year survival is only 8% (Baldwin et al., 2012).  Another study including 17,837 HGSOC patients 
in SEER from 2004-2014 estimates the 5-year survival of HGSOC to be 32% for the distant stage, 
and the 10-year survival to be further reduced by half (L. C. Peres et al., 2019).  
1.1.2  Clinical factors related to survival 
Many clinical factors affect the survival of HGSOC patients in addition to the tumor stage. 
First, optimal surgical debulking, which is defined as no visible cancer or no tumor larger than 1 
cm after debulking surgery (American Cancer Society), is associated with better survival for EOC 
patients and HGSOC patients (Aluloski et al., 2017; Chang, Bristow, & Ryu, 2012; Chang, Hodeib, 
Chang, & Bristow, 2013; Dao et al., 2016). Second, different types of treatment might be 
associated with HGSOC survival, but the effect is unclear. There are two typical treatments for 
EOC patients. One is neoadjuvant chemotherapy, which involves 3 cycles of chemotherapy 
treatment before debulking surgery and then an additional 3-5 cycles of chemotherapy after 
debulking surgery (Inciura et al., 2006). The other is adjuvant chemotherapy, which involves 6-8 
cycles of chemotherapy after surgery (Inciura et al., 2006). Although there is no study estimating 
the effect of different treatments on HGSOC survival, several studies estimated the effect on EOC 
survival. One study, including 925 patients with early-stage EOC, reveals that adjuvant 
chemotherapy is associated with better overall survival (Carlson, 2003). Nevertheless, there is no 
difference found between two types of treatments on survival in another study of 574 patients with 
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advanced OC (Inciura et al., 2006).  Compared to the types of treatment, the response to 
chemotherapy is more important to HGSOC survival. Platinum sensitivity, which is defined as the 
time between the last dose of platinum-based chemotherapy and the evidence of cancer progression 
equal to or larger than 6 months (Matulonis et al., 2016), produces a better survival for HGSOC 
patients (Aluloski et al., 2017; Dao et al., 2016). Studies also reveal that BRCA mutation is not 
only a risk factor of HGSOC but also a factor related to HGSOC survival (Bell et al., 2011; Dao 
et al., 2016; S. I. Kim et al., 2019). Patients with germline BRCA mutations had better prognosis 
(Dao et al., 2016; S. I. Kim et al., 2019).  
Cancer antigen 125 (CA125) is the gold standard of biomarkers for diagnosis and prognosis 
for HGSOC (Akeson et al., 2009; Rein et al., 2011; Salminen et al., 2020). Xu et al. indicate that 
the nadir CA-125 level, defined as the CA-125 values at two weeks after the evaluation at the start 
of diagnosis, is an independent predictor for HGSOC overall survival (Xu et al., 2013). In a recent 
study, Salminen et al. indicate the nadir CA125-STn, instead of CA-125 can predict HGSOC 
survival (Salminen et al., 2020). The authors in a literature review investigated the association of 
CA-125 level at different time-point, including prechemotherapy, post-chemotherapy, during 
chemotherapy, preoperative, postoperative, half-life, with nadir, and ovarian cancer survival 
(Gupta & Lis, 2009).  The authors conclude that the CA-125 level is a significant prognostic factor 
for ovarian cancer overall survival, although the results were controversial (Gupta & Lis, 2009). 
1.1.3  Immunohistochemistry biomarkers of interest 
The Ovarian Tumor Tissue Analysis (OTTA) consortium was formed in 2010 to validate 
prognostic markers by histologic subtypes (Susan J. Ramus et al., 2013). There were 70 study sites 
from North America, South American, Europe, and Asia participating in OTTA. OTTA have 
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conducted two types of large-scale research projects, including immunohistochemistry (IHC) and 
RNA expression. Nine IHC biomarkers associated with EOC survival have been published or 
under review by OTTA, including myeloid differentiation primary response gene 88 (MyD88) 
(Block et al., 2018), Toll-like receptor 4 (TLR4) (Block et al., 2018), Folate receptor 1 (FOLR1) 
(Köbel et al., 2014), CD8+ tumor-infiltrating lymphocytes (CD8+ TILs) (Ovarian Tumor Tissue 
Analysis et al., 2017), p16 (Rambau et al., 2018), phosphatase and tensin homolog (PTEN), 
progesterone receptor (PR) (Sieh et al., 2013), estrogen receptor (ER) (Sieh et al., 2013) and 
androgen receptor (AR). Positive MyD88 is associated with poor HGSOC survival compared to 
negative MyD88 (Block et al., 2018). Positive CD8+ TILs and strong PR expression are associated 
with better HGSOC survival (Ovarian Tumor Tissue Analysis et al., 2017; Sieh et al., 2013). CD8+ 
TILs also have interacted with BRCA mutation on HGSOC survival (Ovarian Tumor Tissue 
Analysis et al., 2017). Although FOLR1 is not associated with HGSOC survival, there is a 
significant interaction between FOLR1 and stage on HGSOC survival (Köbel et al., 2014). 
There is no published result on AR and PTEN by OTTA. However, a study combining 87 
HGSOC and 31 endometrioid, another histology subtype of EOC, finds positive PR and AR are 
associated with overall survival (Jönsson et al., 2015). Lower expression levels of PTEN are 
associated with poor prognosis in HGSOC (Bakkar et al., 2015; Filipe C. Martins et al., 2014; 
Shen, Li, Liu, & Cheng, 2017) because the inactivation of PTEN causes chemotherapy resistance 
(Nero, Ciccarone, Pietragalla, & Scambia, 2019). 
The current study aims to build a prognostic model for HGSOC overall survival by 
identifying the most important prognostic biomarkers from 9 candidate IHC biomarkers in OTTA. 
The model would provide potential opportunities to inform treatment decision making and extend 
the survival of HGSOC patients. 
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1.2 Statistical learning algorithms of variable selection for survival 
1.2.1  Cox proportional hazard regression 
Cox proportional hazard regression analysis (CoxPHR) is usually used to predict survival 




where ℎ0(𝑡) is the baseline hazard when all the predictors, 𝑥𝑖, are equal to 0; ℎ(𝑡) is the expected 
hazard at time 𝑡 , which represent the instantaneous death rate at time 𝑡 ; 𝛽  is the vector of 
regression coefficients.  





By taking the natural logarithm (𝑙𝑛) on both sides of the hazard function, the formula can be 
rewritten as  
𝑙𝑛 ℎ(𝑡) = 𝑙𝑛 ℎ0(𝑡) + 𝑥𝑖
𝑡𝛽. 
Although it is not a generalized linear model (Nelder & Wedderburn, 1972), inference on the 
coefficients 𝛽 can be achieved via partial likelihood without specifying ℎ0(𝑡), the baseline hazard,  
proposed by Cox, 1975 (Cox, 1975).  
The observed dataset is denoted as (𝑦𝑖, 𝛿𝑖, 𝑥𝑖), where 𝑦𝑖 is the observed time, 𝛿𝑖  is the 
failure or right-censoring indicator (1 = failure, 0 = censored), 𝑥𝑖  is a set of predictors. For 
individual with 𝛿𝑖 = 0, the likelihood is  
𝐿𝑖(𝛽) = 𝑆𝑖(𝑦𝑖). 
For individual with 𝛿𝑖 = 1, the likelihood is 
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𝐿𝑖(𝛽) = 𝑆𝑖(𝑦𝑖)ℎ𝑖(𝑦𝑖). 
In both formulas above, 𝑆𝑖(𝑦𝑖) is the survival function, which gives the probability that a patient 
will survived beyond time 𝑦.  
The full likelihood is  


















The seconded and third terms of the full likelihood formula are not relevant to inference 𝛽.  𝛽 is 
derived from the first term of the formula by Cox, which is 

















The likelihood function is called the partial likelihood function. The maximum likelihood 
estimation (MLE) method can be applied to the partial likelihood to calculate 𝛽 (Lai, Hayashida, 
& Akutsu, 2013). The estimated 𝛽, denoted as  ?̂?, maximizes the log partial likelihood function 
and therefore, it is named as the maximum partial likelihood estimator (MPLE).  
1.2.2  CoxPHR model with lasso penalty for variable selection (glmnet package) 
The sample size, 𝑛, normally is larger than the number of predictors, 𝑝. However, if 𝑛 ≫
𝑝 is not satisfied, prediction performance could suffer if too many nonimportant predictors are 
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included in the model. Additionally, high correlation between predictors may occur due to the 
inclusion of redundant variables. Hence, a subset of predictors should be selected. A regularization 
term, which is imposing a cost on the optimization function to prevent overfitting, can be added to 
the partial likelihood function to reach this goal. The current study uses the least absolute shrinkage 
and selection operator (lasso) estimator, which is an 𝐿1- penalized estimator (Tibshirani, 1996). 
The 𝐿1 norm, as known as Manhattan Distance norm, is the sum of the magnitudes of the vectors 
in a space. 
The 𝐿1 norm of 𝛽 is defined as  
∥ 𝛽 ∥1   = ∑|𝛽𝑗|
𝑗
. 
To estimate 𝛽 with variable selection, the question is now to search for 𝛽 which maximize 
the partial likelihood  











subject to ∑ |𝛽𝑗|𝑗 ≤ 𝑠 .  
Friedman et al., 2010 provided the glmnet packaged in R to fit lasso and other 
regularization paths for the CoxPHR model (Friedman, Hastie, & Tibshirani, 2010). In glmnet, the 
equivalent question is written as  
arg max
𝛽
𝑙(𝛽) − ∑ λ[(1 − α) ∥ 𝛽 ∥2




where 𝑙(𝛽)  is the log partial likelihood, λ  is the tuning parameter to controls the penalty; 
∑ λ[(1 − α) ∥ 𝛽 ∥2
2/2 + α ∥ 𝛽 ∥1]
𝑝
𝑗=1  is the elastic net penalty, including the 𝐿1 norm (lasso) and 
𝐿2 norm (ridge) penalties. When α is set to 1, which is the default in glmnet package, the lasso 
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penalty is applied. The current study uses the 𝐿1 norm penalty because the 𝐿1 norm penalty can 
force some of the coefficient estimates to be exactly equal to zero when the tuning parameter, 𝜆, 
is sufficiently large. The lasso performers the best subset selection. 
CoxPHR model with lasso penalty has strengths over stepwise regression, another widely 
used method to selection predictive variables. There are three main approaches for stepwise 
regression, forward selection, backward elimination, and bidirectional procedure. The algorithm 
used with all three approaches proposed by Efroymson in 1960 is an automated procedure to select 
variables based on some prespecified criteria, such as t statistics, AIC, BIC and adjusted R2 
(Efroymson, 1960). However, using different prespecified criteria could produce different sets of 
selected variables. Forward stepwise and backward stepwise selection approaches generally cannot 
produce identical models (Gareth James, 2013). Moreover, stepwise regression does not work well 
when 1) the predictors are correlated, or 2) the number of parameters is larger than that of the 
number of observations. The CoxPHR model with lasso penalty can still conduct variable selection 
in these two situations, and it has a more systematic method for generating a sequence of candidate 
models through the tuning of shrinkage parameter 𝜆 . For example, 𝜆 = 0  corresponds to the 
saturated model with no variable selection, and the model becomes sparse and more parsimonious 
as 𝜆  increases. Another strength of the CoxPHR model with lasso penalty is computational 
efficiency to explore the best combinations from many parameters.  
1.2.3  Tuning parameter selection (glmnet package) 
Cross-validation to select the tuning parameter, 𝜆, is built in the glmnet package. The 
methods of measurement include deviance and Harrell’s C-index for the CoxPHR model. The 
deviance is defined using the partial-likelihood for CoxPHR model in cv.glmnet function. 
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Harrell’s C-index, also known as the concordance index, proposed by Harrell et al., 1982, 
is used to assess the goodness of fit of the CoxPHR model (F. E. Harrell, Jr., Califf, Pryor, Lee, & 
Rosati, 1982). A prognostic score for each patient, denoted as 𝜂, is defined as 𝑥𝑖
𝑡𝛽. A higher 
prognostic score should be related to a longer survival time. Harrell’s C-index quantifies the 
correlation between the prognostic sore, 𝜂, and survival time, 𝑇. 
For two patients 𝑖 and 𝑗 ( 𝑖 ≠ 𝑗), three scenarios could happen.  
- In scenario 1, both had an event during the follow-up time. A concordant pair is 
identified when  η𝑖 > η𝑗  and   𝑇𝑖 > 𝑇𝑗 . A discordant pair is identified when η𝑖 >
η𝑗  and   𝑇𝑖 < 𝑇𝑗. 
- In scenario 2, both were censored. Since it is unknown which one had a longer survival 
time, the pair of patients is not be counted. 
- In scenario 3, the patient 𝑖 was censored, and the patient 𝑗 had an event. If 𝑇𝑖 > 𝑇𝑗 , a 
concordant pair is identified when  η𝑖 > η𝑗, and a discordant pair is identified when 
η𝑖 < η𝑗. If  𝑇𝑖 < 𝑇𝑗, the pair of patients is not be counted. 
All possible pairs of patients must be investigated. Harrell’s C-index is calculated as 
𝐶 − 𝑖𝑛𝑑𝑒𝑥 =  
# 𝑐𝑜𝑛𝑐𝑜𝑟𝑑𝑎𝑛𝑡 𝑝𝑎𝑖𝑟𝑠
# 𝑐𝑜𝑛𝑐𝑜𝑟𝑑𝑎𝑛𝑡 𝑝𝑎𝑖𝑟𝑠 +  # 𝑑𝑖𝑠𝑐𝑜𝑟𝑑𝑎𝑛𝑡 𝑝𝑎𝑖𝑟𝑠
 
C-index ranges from 0 to 1. The value of C-index less than 0.5 means that the model’s 
prediction ability is no better than a random chance. A value of C-index close to 1 means that the 
model has an excellent goodness-of-fit.  
The cv.glmnet function in the glmnet package in  returns the mean cross-validated C-index 
and the estimate of the standard error of the mean cross-validated C-index. The cv.glmnet function 
returns all values of the tuning parameter, 𝜆, used in the fit, and also specifies the value that gives 
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the maximum mean cross-validated C-index, 𝑙𝑎𝑚𝑏𝑑𝑎. 𝑚𝑖𝑛, and that gives the C-index within one 
standard error of the maximum, 𝑙𝑎𝑚𝑏𝑑𝑎. 1𝑠𝑒. The later, 𝑙𝑎𝑚𝑏𝑑𝑎. 1𝑠𝑒, is more often to use to 
select the best model (Friedman et al., 2010).  
1.2.4  Additional validation and calibration (rms package) 
The rmc packaged developed by Frank Harrell can be used to evaluate the prediction ability 
of a fitted CoxPHR model (F. E. Harrell, 2006).  In the current study, the functions, validate.cph 
and calibrate, are used to validate the fitted Cox prognostic model in the test set. The resampling 
methods built in the two functions include cross-validation, bootstrap, 0.632 resampling, and 
randomization. Resampling approaches involves repeatedly drawing samples from a training set 
and fitting the same statistical method multiple times. The function, validate.cph, returns a bias-
corrected 𝐷𝑥𝑦  index, which equal to 2 × (𝐶 − 𝑖𝑛𝑑𝑒𝑥 − 0.5).  The function, calibrate, gives a 
curve comparing the predicted probabilities to the observed probabilities at a specified time point.  
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2.0 Method 
2.1 Patients and clinical variables 
A total of 5,944 patients diagnosed with invasive HGSOC and enrolled in the collaborative 
studies participating in the OTTA consortium were considered eligible in the analysis. The site-
specific Institutional Review Boards approved study protocols. Inclusion criteria included the 
availability of tissue microarrays (TMAs) for IHC analysis, clinical follow-up data, age at 
diagnosis, tumor stage, and debulking status. Clinical data were obtained from medical records, 
cancer registries, death certificates, and pathology reports. There were 129 cases with missing data 
for stage there were excluded from the analysis. There were 254 cases with complete data for 9 
IHC biomarkers and 5,561 cases with at least one missing IHC biomarker. Data from the 
participating study sites were centrally harmonized. 
2.2 Immunohistochemistry (IHC) 
Tumors were obtained at initial debulking surgery and arrayed on TMAs. Stained slides of 
TMAs were centralized and performed at the Mayo Clinic (Rochester, Minnesota) for MyD88, 
TLR4 and CD8 TILs, at Leica Microsystems (Wetzlar, Germany) for FOLR1, and at Genetic 
Pathology Evaluation Centre (Vancouver, BC, Canada) for ER and PR. The information on PTEN 
and AR is not available. Details are given in the published studies (Block et al., 2018; Köbel et al., 
2014; Ovarian Tumor Tissue Analysis et al., 2017; Rambau et al., 2018; Sieh et al., 2013).  
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Two observers score the staining intensity for each IHC. For AR, a 2-tiered system 
(negative and positive) was used. ER and PR were scored using a 3-tiered system (<1%, 1 to 50%, 
and >50% of tumor cell nuclei positive). For p16 expression, a 3- tiered system was used (<1%, 1 
to 75%, and >75% of tumor cell nuclei positive). MyD88, TLR4 and PTEN were scored using a 
4-tiered system (negative, week, moderate and strong expression). CD8 TILs were scored into a 
4-tiered system (none, 1-2 IEL/40 x HPF, 3-19 IEL/40 x HPF, and >=20 IEL/40 x HPF). FOLR1 
was scored into a 6-tiered system (absent, weak, 1-50% irrespective of subcellular localization, 
>50% with membranous localization, 50-95% with cytoplasmic staining and >95% with 
cytoplasmic staining). A preliminary analysis was conducted to compare the association between 
IHC biomarkers and HGSOC survival in published OTTA paper using CoxPHR model adjusting 
for study site, age (continuous), stage (I/II and III/IV) and debulking status (optimal, suboptimal, 
and unknown)  in STATA SE 16.1. 
2.3 Analysis 
The goal of this thesis was to build a prognostic model for HGSOC overall survival. To 
achieve this, the following steps were used: step 1) split the dataset into the training set and test 
set; step 2)  fit a CoxPHR model with lasso penalty in the training set to identify the most important 
individual predictors from clinical variables and IHC biomarkers; step 3) select the best model 
from models with age, stage and building status (model 0 ), the dummy variables selected by lasso 
(model 1), the dummy variables selected by lasso with other dummy variables grouped in the 
categorical variables (model 2), and further adjusting  for study site (model 3); step 4)  conduct 
external validation in the test set; and step 5)  visualize the final prognostic model. 
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2.3.1  Training set and test set 
There were total 5944 HGSOC cases from OTTA. Cases with missing stage were excluded 
from the current study, leaving 5815 cases. The training set contained 254 cases with complete 
data for 9 IHC biomarkers from HOP (Lo-Ciganic et al., 2012), MAL (Glud et al., 2004), NOT 
(Williams, Martin, Moss, Durrant, & Deen, 2012), TUE, UKO (Balogun et al., 2011) and VAN 
(Köbel et al., 2010; Prentice et al., 2007). After the step of variable selection, 1563 cases with data 
in the selected IHC biomarkers compose the test set from AOV(Kelemen, Köbel, Chan, Taghaddos, 
& Dinu, 2013; Köbel et al., 2014), BAV (Song et al., 2009), BRZ, CAL (Bromley et al., 2012), 
CNI (Kamieniak et al., 2015), GER (Royar, Becher, & Chang-Claude, 2001), HAW (Goodman, 
Lurie, Thompson, McDuffie, & Carney, 2008; Lurie et al., 2008), HOP (Lo-Ciganic et al., 2012), 
LAX (S. J. Ramus et al., 2012), MAL (Glud et al., 2004), MAY (Goode et al., 2010; Kelemen et 
al., 2008), NOT (Williams et al., 2012), POC (Garcia-Closas et al., 2007), TUE, UKO (Balogun 
et al., 2011), VAN (Köbel et al., 2010; Prentice et al., 2007) and WMH (Emmanuel et al., 2014) 
(Appendix Table 1). The left 5561 cases were in the candidates’ pool. After variables selection 
by Lasso, 1563 cases with selected IHC biomarkers from the candidates’ pool were in the test set 
(Figure 1). Student’s t-test was used to compare age at diagnosis (continuous), and Chi-square test 
was used to compare stage (I/II and III/IV), debulking status (optimal, suboptimal, and unknown) 
and 9 IHC biomarkers between cases in the training set and in the candidates’ pool. The statistical 
tests were two-sided and conducted using STATA SE 16.1.  
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Figure 1 Cases election for taining set and test set 
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2.3.2  Variable selection 
Data from the training set was used to fit in the CoxPHR model with lasso penalty using 
the glmnet package in R software. Because the cv.glmnet function cannot perform the CoxPHR 
model with grouped lasso penalty (i.e. does not accommodate categorical variables with more than 
two levels directly), the model.matrix function was used to create the predictor matrix with dummy 
variables. Thus, each level of the original categorical variables was treated as an individual 
predictor and could potentially be selected in the prediction models. From the original training set, 
the predictor matrix contained 29 predictors not including intercept, because a CoxPHR model 
does not contain an intercept. The default 10-fold cross-validation was used to select the tuning 
parameter based on the C-index. The C-index corresponding to the tuning parameter that gives 
error within one standard error of the maximum was chosen.  
2.3.3  Model selection and internal validation 
The rms package in R software is used to refit and evaluate four CoxPHR models: model 
0 as a baseline model using age and the clinical variables, such as stage and debulking status,  
model 1 using the dummy variables selected by lasso, model 2 using the dummy variables selected 
by lasso with other dummy variables grouped in the categorical variables, and model 3 further 
adjusting for study sites. Because Surv function in the package cannot adjust the bias induced by 
left truncation, the follow-up duration is corrected by the date of death or the date of last known to 
be alive since the date of diagnosis minus the date of interviews since the date of diagnosis. The 
computation of corrected follow-up duration was checked in STATA SE 16.1. The estimated 
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parameters using the corrected follow-up duration are close to those from stset function dealing 
with left-truncation data in STATA SE 16.1.  
The goodness of fit for a model was determined by C-index as well as calibrations of 1-
year, 2- year, 3- year and 5-year survival using 500 bootstrap samples. The internal validation was 
implemented by validate and calibrate functions built in the rms package. 
2.3.4  External validation 
Student’s t-test was used to compare age at diagnosis (continuous), and Chi-square test was 
used to compare stage (I/II and III/IV), debulking status (optimal, suboptimal, and unknown) and 
9 IHC biomarkers among the test set, training set and excluded cases. Kaplan-Meier curves were 
visually compared to assess differences in survival. The statistical tests were two-sided and 
conducted using STATA SE 16.1.  
2.3.5  Final model and nomogram 
The final CoxPHR model estimated the hazard ratios (HRs) and 95% confidence intervals 
(CIs) of the selected clinical variables and IHC biomarkers using the test set. Kaplan-Meier curves 
visually compared survival across each categorical variable adjusted for other covariates to 
estimate the proportional hazards assumption. Wald test were performed to test the linear trend for 
selected IHC biomarkers in the final model. The tests were implemented in STATA SE 16.1. The 
goodness of fit for the refitted model in the test set was determined by C-index as well as 
calibrations of 1-year, 2- year, 3- year and 5-year survival using 500 bootstrap samples. Receiver 
operating characteristic (ROC) curves with area under the curve (AUC) corresponding to the 
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predictions on 1-year, 2- year, 3- year and 5-year survival were presented using the timeROC 
package in R software. 
The prognostic model was also fitted using the rms package in R software. Based on the 
calibration of 1-year, 2- year, 3- year and 5-year survival, a nomogram to predict 3-year and 5-
year survival of patients with HGSOC is obtained by nomogram function. The nomogram gives a 
prognostic index calculated by summing the number of the risk points corresponding to each 
weighted covariate in the prognostic model. The possibility of the 3-year and 5-year survival for 
each patient can be subsequently calculated based on the prognostic index.  
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3.0 Results 
3.1 Preliminary analysis for IHC biomarkers 
The associations between IHC biomarkers and HGSOC survival in the current study are 
similar to the results from published OTTA study (Table 1). Strong expression of MyD88 in the 
tumor cells is associated with higher hazard of HGSOC death (HR 1.13, 95% CI 1.02- 1.26). 
Expression of CD8 is inversely associated with hazard of HGSOC death. However, strong 
expression of PR is not associated with HGSOC survival in the current data (HR 0.85, 95% CI 
0.68-1.05), although Sieh et al. indicated a significant association between strong expression of 
PR and HGSOC survival (Sieh et al., 2013). All published OTTA studies adjusted for study site, 
age and stage in their models. Studies estimating the association between FOLR1 and p16 also 
adjusted for residual disease after surgery (Köbel et al., 2014; Rambau et al., 2018). The 
discrepancies on the effect of PR and ER on HGSOC survival between the current study and 
Sieh et al.’s study could be due to that Sieh et al. further adjusted for age-squared in the Cox 
model (Sieh et al., 2013).  
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Table 1 Comparing the association between IHC biomarkers and HGSOC survival to the published OTTA study 
IHC 
biomarkers 
OTTA  Current study 
Level N (%) HR (95% CI) Confounders Level N (%) 
HR (95% 
CI)1 
MyD88  Weak 712 (26) ref Adjusted for study, age 
(continuous) and stage 
(I/II, III/IV. Unknown) 
Negative/ weak 769 (25.41) ref 
(Block et al., 
2018) 








TLR4 Weak 734 (29) ref Adjusted for study, age 
(continuous) and stage 
(I/II, III/IV. Unknown) 
Negative/ weak 768 (28.80) ref 
(Block et al., 
2018) 













358 (23.8) ref 
Stratified by study and 





missing) and FIGO 
















membranous >50%,  
cytoplasmic50-95%,  





CD8+ Negative (none) 546 (17.1) ref 
Adjusted for study, age 
(continuous), and stage 
(I/II, III/IV, unknown) 
























 High  










Heterogeneous 1550 (37.9) ref 
Adjusted for study, age, 
time interval, stage and 
residual tumor 
Negative (<1%) 269 (6.61) ref 
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 Absent 244 (6.0) 
1.06 
(0.90, 1.25) 















Negative 1144 (68.9) ref Stratified by site, and 
adjusted for age, age-
squared, and stage 
(localized, regional, 





(Sieh et al., 
2013) 
Weak 393 (23.7) 
1.02 
(0.89, 1.18) 
Weak 421 (25.29) 
1.05 
(0.92, 1.19) 
 Strong 124 (7.5) 
0.71 
(0.55, 0.91) 





Negative 326 (19.3) ref Stratified by site, and 
adjusted for age, age-
squared, and stage 
(localized, regional, 
advanced) at diagnosis 
Negative 350 (20.73) ref 
(Sieh et al., 
2013) 
Weak 347 (20.5) 
1.08 
(0.89, 1.31) 
Weak 360 (21.33) 
0.93 
(0.78, 1.11) 
  Strong 1018 (60.2) 
1.05 
(0.89, 1.24) 
Strong 978 (57.94) 
0.94 
(0.81, 1.08) 
CI, confidence interval; HR, hazard ratio; IEL, intraepithelial lymphocytes; IHC, Immunohistochemistry; ref, reference. 
1 Adjusting for study site, age as continuous, stage (I/II and III/IV) and debulking status (optimal, suboptimal, and unknown)   
s
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3.2 Clinical characteristics of patients 
Out of 5815 cases, 254 patients with HGSOC from 6 sites in OTTA are included in the 
variable selection process. The characteristics of these patients are presented in Table 2. The 
participating studies and case ascertainment are summarized in Appendix Table 1. The median 
OS is 5.04 years (95% CI 4.36-5.99), which is longer than the median OS among cases in the 
candidates’ pool, 3.50 years (95% CI 3.36-3.63). Of the 254 cases, 124 (48.82%) have more 
advanced stage. While 82.84% of cases in candidates’ pool are in stage III/ IV (P<0.001). There 
are 56.69% of cases and 34.11% cases with an optimal debulking status in the training set and in 
the candidates’ pool, respectively. 
AR expression is seen in 43.31% HGSC cases in the training set. Nearly half cases 
(48.03%) have ER expression in >50% tumor cells in the training set. More than 70% of cases 
have a moderate or strong intensity of TLR4 and MyD88 expression. FOLR1 expression is not 
presented in 36 cases and is weakly presented in 40 cases, while 88 cases have FOLR1 expression 
in >50% of tumor cells with cytoplasmic staining. 90 cases (35.43%) had 3-19 IEL/40 * HPF of 
CD8+ and 70 (27.56%) cases have more than 20 IEL/40 * HPF.  More than 60% of cases have PR 
expression in <1% tumor cells, which is close to the percentage in the candidates’ pool (P = 0.169). 




Table 2 Demographic and immunohistochemistry characteristics of patients with invasive high grade serous 















Overall survival, years     
median (95% CI) 3.58 (3.43, 3.70) 5.04 (4.36, 5.99) 3.50 (3.36, 3.63) <0.001 
Age (year), mean (SD)     
mean (SD) 60.22 (10.71) 60.28 (11.26) 60.22 (10.68) 0.9345 
Stage     
stage I/II 1084 (18.64) 130 (51.18) 954 (17.16) <0.001 
stage III/IV 4731 (81.36) 124 (48.82) 4607 (82.84)  
Debulking Status     
optimal 2041 (35.10) 144 (56.69) 1897 (34.11) <0.001 
suboptimal 526 (9.05) 7 (2.76) 519 (9.33)  
unknown 3248 (55.86) 103 (40.55) 3145 (56.55)  
Immunohistochemistry     
Androgen Receptor     
negative 2308 (65.57) 144 (56.69) 2164 (66.26) 0.002 
positive 1212 (34.43) 110 (43.31) 1102 (33.74)  
missing 3739 - 3739  
Estrogen Receptor     
<1% of tumor cells 350 (20.73) 68 (26.77) 282 (19.67) 0.002 
1 to 50% of tumor cell 
nuclei positive 
360 (21.33) 64 (25.20) 296 (20.64) 
 
> 50% of tumor cells 
positive 
978 (57.94) 122 (48.03) 8856 (59.69) 
 
missing 4127 - 4127  
Progesterone Receptor     
<1% of tumor cells 1694 (61.40) 158 (62.20) 1536 (61.32) 0.169 
1 to 50% of tumor cell 
nuclei positive 
815 (29.54) 66 (25.98) 749 (29.90) 
 
> 50% of tumor cells 
positive 
250 (9.06) 30 (11.81) 220 (8.78) 
 
missing 3306 - 3306  
Toll-like receptor 4, TLR4     
negative 306 (11.47) 22 (8.66) 284 (11.77) 0.001 
weak intensity 462 (17.32) 38 (14.96) 424 (17.57)  
moderate intensity 1735 (65.05) 190 (74.80) 1545 (64.03)  
strong intensity 164 (6.15) 4 (1.57) 160 (6.63)  
missing 3148 - 3148  
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Myeloid differentiation 
primary response 88, MyD88 
  
 
negative 361 (11.93) 43 (16.93) 318 (11.47) 0.004 
weak intensity 408 (13.48) 24 (9.45) 384 (13.85)  
moderate intensity 1409 (46.56) 130 (51.18) 1279 (46.14)  
strong intensity 848 (28.02) 57 (22.44) 791 (28.54)  
missing 2789 -   
Folate receptor alpha, 
FOLR1 
   
 
absent 175 (11.05) 36 (14.17) 139 (10.45) 0.017 
weak staining 200 (12.63) 40 (15.75) 160 (12.03)  
1–50% of tumor cells 
irrespective of subcellular 
localization 
400 (25.25) 51 (20.08) 349 (26.24) 
 
>50% of tumor cells with 
membranous localization 
299 (18.88) 39 (15.35) 260 (19.55) 
 
50–95% of tumor cells with 
cytoplasmic staining 
375 (23.67) 71 (27.95) 340 (22.86) 
 
>95% of tumor cells with 
cytoplasmic staining  
135 (8.52) 17 (6.69) 118 (8.87) 
 
missing 4231 - 4231  
Phosphatase and tensin 
homolog, PTEN 
   
 
negative 587 (19.05) 32 (12.60) 555 (19.63) 0.049 
weak intensity 1544 (50.10) 137 (53.94) 1407 (49.75)  
moderate intensity 773 (25.08) 67 (26.38) 706 (24.96)  
strong intensity 178 (5.78) 18 (7.09) 160 (5.66)  
missing 2733 - 2733  
Cluster of differentiation 8, 
CD8 
   
 
no IEL 588 (17.36) 53 (20.87) 535 (17.08) 0.018 
1-2 IEL/40 x HPF 577 (17.04) 41 (16.14) 536 (17.11)  
3-19 IEL/40 x HPF 1476 (43.58) 90 (35.43) 1386 (44.24)  
20 or more IEL/40 x HPF 746 (22.03) 70 (27.56) 676 (21.58)  
missing 2428 - 2428  
p16     
<1% of tumor cells 269 (6.61) 15 (5.91) 254 (6.65) 0.525 
 1 to 75% of tumor cell 
nuclei positive 
1534 (37.68) 104 (40.94) 1430 (37.46) 
 
> 75% of tumor cells 
positive 
2268 (55.71) 135 (53.15) 2133 (55.88) 
 
missing 1744 - 1744  
IEL, intraepithelial lymphocytes     
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3.3 Variable selection for the prognostic model 
The tuning parameter was selected based on C-index using 10-fold cross-validation 
(Figure 2). The tuning parameter that gave the C-index within one standard error of the maximum 
is 0.083 corresponding to the C-index of 0.6471 (standard error 0.02103). 
 
Figure 2 Trend of C-index with the different tuning parameter, lambda 
Of 28 dummy variables, 8 variables with non-zero coefficients are selected (Table 3) 
according to the tuning parameter that gives the C-index within one standard error of the 
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maximum. The third level of TLR4 expression, the third and fourth level of CD8+ TILs, and the 
second level of p16 expression out of the dummy IHC variables are selected.  
 
Table 3 Aossiciaton of overall survival with clinical and  immunohistochemistrical variables of patients with 
HGSOC selected from the CoxPHR model with Lasso penalty 
 Predictors β 
Age (year), mean (SD) 0.0018 
Stage  
Stage I/II ref 
Stage III/IV 0.8125 
Debulking Status  
Optimal ref 
Suboptimal 0.3204 
Unknown Not selected 
Immunohistochemistry   
Androgen Receptor  
Negative ref 
Positive -0.0901 
Toll-like receptor 4, TLR4  
negative ref 
weak intensity Not selected 
moderate intensity -0.0418 
strong intensity Not selected 
Cluster of differentiation 8, CD8  
no IEL ref 
1-2 IEL/40 x HPF Not selected 
3-19 IEL/40 x HPF -0.0464 
20 or more IEL/40 x HPF -0.0750 
p16  
<1% of tumor cells ref 
 1 to 75% of tumor cell nuclei positive -0.0540 
> 75% of tumor cells positive Not selected 
IEL, intraepithelial lymphocytes.  
 
Table 4 indicates the predictors in four refitted Cox models using age, stage and debulking 
status (Model 0), using dummy variables selected by lasso (Model 1), using the dummy variables 
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selected by lasso with other dummy variables grouped in the categorical variables (Model 2), and 
further adjusting for study site (Model 3), respectively. Table 5 presents the parameters from four 
refitted Cox models. C-index from 500 bootstrap validation samples are 0.6611, 0.6922, 0.6863 
and 0.6877 for Model 0, Model 1, Model 2 and Model 3, respectively. Further adjusting for study 
site does not improve C-index. The estimated βs from Model 1 (Table 5) are smaller than the 
estimates from the CoxPHR model with lasso penalty (Table 3) because lasso shrinks βs towards 
to zero.  
 
Table 4 Predictors in three models 
Variables  Model 0 Model 1 Model 2 Model 3 
Age (year) as continuous variable Yes Yes Yes Yes 
Stage     
Stage I/II ref ref ref ref 
Stage III/IV Yes Yes Yes Yes 
Debulking Status     
Optimal ref ref ref ref 
Suboptimal Yes Yes Yes Yes 
Unknown Yes No Yes Yes 
Immunohistochemistry     
Androgen Receptor     
Negative No ref ref ref 
Positive No Yes Yes Yes 
Estrogen Receptor     
<1% of tumor cells No No No No 
1 to 50% of tumor cell nuclei positive No No No No 
> 50% of tumor cells positive No No No No 
Progesterone Receptor     
<1% of tumor cells No No No No 
1 to 50% of tumor cell nuclei positive No No No No 
> 50% of tumor cells positive No No No No 
Toll-like receptor 4, TLR4     
negative No ref ref ref 
weak intensity No No Yes Yes 
moderate intensity No Yes Yes Yes 
strong intensity No No Yes Yes 
Myeloid differentiation primary 
response 88, MyD88 
    
negative No No No No 
weak intensity No No No No 
moderate intensity No No No No 
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strong intensity No No No No 
Folate receptor alpha, FOLR1     
absent No No No No 
weak staining No No No No 
1–50% of tumor cells irrespective of 
subcellular localization 
No No No No 
>50% of tumor cells with membranous 
localization 
No No No No 
50–95% of tumor cells with cytoplasmic 
staining 
No No No No 
>95% of tumor cells with cytoplasmic 
staining  
No No No No 
Phosphatase and tensin homolog, PTEN     
negative No No No No 
weak intensity No No No No 
moderate intensity No No No No 
strong intensity No No No No 
Cluster of differentiation 8, CD8     
no IEL No ref ref ref 
1-2 IEL/40 x HPF No No Yes Yes 
3-19 IEL/40 x HPF No Yes Yes Yes 
20 or more IEL/40 x HPF No Yes Yes Yes 
p16     
<1% of tumor cells No ref ref ref 
 1 to 75% of tumor cell nuclei positive No Yes Yes Yes 
> 75% of tumor cells positive No No Yes Yes 
Study Site as categorical variable No No No Yes 
 














Age (year), mean (SD) 0.0138 0.0098 0.0104 0.0090 
Stage     
Stage I/II ref ref ref ref 
Stage III/IV 1.0599 1.0613 0.9899 0.9778 
Debulking Status     
Optimal ref ref ref ref 
Suboptimal 1.3696 1.2421 1.2711 1.7723 
Unknown 0.1999 NA 0.2811 1.1230 
Immunohistochemistry        
Androgen Receptor     
Negative NA ref ref ref 
Positive NA -0.3739 -0.2938 -0.2445 
Toll-like receptor 4, TLR4     
negative NA ref ref ref 
weak intensity NA NA -0.0631 0.0076 
moderate intensity NA -0.0882 -0.1775 -0.0293 
28 
strong intensity NA NA -0.0367 0.2429 
Cluster of differentiation 8, 
CD8 
 
   
no IEL NA ref ref ref 
1-2 IEL/40 x HPF NA NA -0.4566 -0.5428 
3-19 IEL/40 x HPF NA -0.5788 -0.8490 -0.9284 
20 or more IEL/40 x HPF NA -0.7084 -0.9223 -0.9792 
p16     
<1% of tumor cells NA ref ref ref 
 1 to 75% of tumor cell 
nuclei positive 
NA 
-0.2959 -0.1360 0.2084 
> 75% of tumor cells 
positive 
NA 
NA 0.2902 0.5640 
Dxy 0.3221 0.3844 0.3726 0.3753 
C-index 0.6611 0.6922 0.6863 0.6877 
IEL, intraepithelial lymphocytes; NA, not applicable 
1 adjust for study site     
 
The calibration of 1-year, 2-year, 3-year and 5-year survival predicted by Model 1 and 
Model 2 are presented in Figure 3. The mean errors of model 1 was 0.017 for 3-year survival and 
0.033 for 5-year survival. The mean errors of model 1 was 0.026 for 3-year survival and 0.035 for 
5-year survival. Compared to Model 2, Model 1 has a slightly better performance to predict the 
survival of HGSOC for 3-year and 5-year survival, but Model 2 is more interpretable. Thus, Model 
2, as the final prognostic model, was used for external validation. 
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Figure 3 Calibration of 1-year, 2-year, 3-year and 5-year survival for Model 1 and Model 2 in the training set 
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3.4 External validation  
A total of 1,563 patients with data in AR, TLR4, CD8 and p16 expression in 17 study 
sites from OTTA (Appendix Table 1) were used as a test set to perform the external validation. 
The median OS in the test set is 3.41 years (95 % CI 3.21-3.63 years), which is significantly 
shorter than the OS in the training set (5.41 years, 95% CI 4.36-5.99) but closes to the excluded 
cases (3.55 years, 95% CI 3.34-3.73) (Figure 4). 
 
Figure 4 Kaplan–Meier curves for the test set, training set and excluded cases 
The test set shares similar distributions of age, AR and p16 expression as the training set. 
Patients in the test set are likely to be in an advanced stage and had suboptimal debulking status 
(Table 6). TLR4 is not expressed in 14.78% cases and weakly expressed in 18.04% cases in the 
test set, compared to 8.66% and 14.96% in the training set. Cases in test set have less absent CD8+ 
TILs (14.84%), but also less 20 or more IEL/40 x HPF (23.42%) compared to cases in the training set, 
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20.87% and 27.56%, respectively.  Compared to the excluded cases, cases in the test set are more like to be 
older (mean 61.21 vs. 59.83 of excluded cases, P <0.0001) and have optimal debulking status (45.55% vs. 
29.64 of excluded cases, P < 0.001). However, the percentages of cases in stage I/II are close to each other 
(16.44% in the test set vs. 17.43% of excluded cases, P = 0.378).  
Table 6 Comparison of selected demographic and immunohistochemistry characteristics of patients between 
the test set, training set and exlcuded cases 
Variables 
Test set 
















test set to 
excluded 
cases 
Overall survival, years      









Age (year), mean (SD)      
mean (SD) 61.21 (11.25) 60.28 (11.26) 0.2211 59.83 (10.43) <0.0001 
Stage      
Stage I/II 257 (16.44) 130 (51.18) <0.001 697 (17.43) 0.378 
Stage III/IV 1306 (83.56) 124 (48.82)  3301 (82.57)  
Debulking Status      
Optimal 712 (45.55) 144 (56.69) <0.001 1185 (29.64) <0.001 
Suboptimal 189 (12.09) 7 (2.76)  330 (8.25)  
Unknown 662 (42.35) 103 (40.55)  2483 (62.11)  
Immunohistochemistry  
Androgen Receptor      
negative 959 (61.36) 144 (56.69) 0.158 1205 (70.76) <0.001 
    positive 604 (38.64) 110 (43.31)  498 (29.24)  
missing - -  2295  
Toll-like receptor 4, 
TLR4 
     
negative 231 (14.78) 22 (8.66) <0.001 53 (6.24) <0.001 
weak intensity 282 (18.04) 38 (14.96)  142 (16.71)  
moderate intensity 934 (59.76) 190 (74.80)  611 (71.88)  
strong intensity 116(7.42) 4 (1.57)  44 (5.18)  
missing    3148  
Cluster of 
differentiation 8, CD8 
     
no IEL 232 (14.84) 53 (20.87) 0.01 303 (19.30) 0.002 
1-2 IEL/40 x HPF 260 (16.63) 41 (16.14)  276 (17.58)  
3-19 IEL/40 x HPF 705 (45.11) 90 (35.43)  681 (43.38)  
20 or more IEL/40 x 
HPF 
366 (23.42) 70 (27.56)  310 (19.75)  
32 
missing - -  2428  
p16      
<1% of tumor cells 77 (4.93) 15 (5.91) 0.631 177 (7385) 0.001 
 1 to 75% of tumor 
cell nuclei positive 
611 (39.09) 104 (40.94)  819 (36.34)  
> 75% of tumor cells 
nuclei positive 
875 (55.98) 135 (53.15)   1258 (55.81)  
missing - -  1744  
IEL, intraepithelial 
lymphocytes 
     
3.5 Final model and visualization 
Due to a high discrepancy on survival time between the test set and training set, the hazard ratio 
of OS with age, stage, debulking status, AR, TLR4, CD8+ TILs and p16 expression from the 
prognostic model refitting in the test set are obtained (Table 7). The hazard is 2.40 times (95 CI% 
1.96-2.93) higher for patients in stage III/IV compared to patients in I/II. The suboptimal debulking 
status increases the 1.47 times of hazard of death (95% CI 1.21-1.78) compared to the optimal 
debulking status. Higher density of CD8+ TILs is associated with lower hazard of death (0.92, 
0.88, 0.72 for 1-2 IEL/40 x HPF, 3-19 IEL/40 x HPF and 20 or more IEL/40 x HPF compared to 
no IEL, P for trend =0.0011). Although TLR4 and p16 expression status are also selected to build 
the prognostic model, no significant association of TLR4 or p16 expression levels to the OS was 
found. Positive AR expression is associated with a 18% lower hazard of death compared to 




Table 7 Association of overall survival with selected clinical and  immunohistochemistry variables of the 
predict Cox model 
 Variables Hazard Ratio (95% CI) 
Age as continuous 1.02 (1.02, 1.03) 
Stage  
Stage I/II ref 
Stage III/IV 2.40 (1.96, 2.93) 
Debulking Status  
Optimal ref 
Suboptimal 1.47 (1.21, 1.78) 
Unknown 1.48 (1.30, 1.68) 
Immunohistochemistry  
Androgen Receptor  
Negative ref 
Positive 0.92 (0.81, 1.04) 
Toll-like receptor 4, TLR4  
negative ref 
weak intensity 1.07 (0.86, 1.32) 
moderate intensity 1.04 (0.87, 1.24) 
strong intensity 1.03 (0.79, 1.35) 
Cluster of differentiation 8, CD8  
no IEL ref 
1-2 IEL/40 x HPF 0.92 (0.75, 1.13) 
3-19 IEL/40 x HPF 0.88 (0.74, 1.04) 
20 or more IEL/40 x HPF 0.72 (.59, 0.88) 
p16  
<1% of tumor cells ref 
 1 to 75% of tumor cell nuclei positive 0.91 (0.68, 1.21) 
> 75% of tumor cells nuclei positive 0.91 (0.68, 1.20) 
C-index 0.6309 
IEL, intraepithelial lymphocytes  
 
Kaplan-Meier curves comparing survival across categories of each variable from the final 
model adjusting for age and the other variables are presented in Figure 5. In each panel, curves in 
each panel, except for AR, do not cross each other, which indicates that the proportional hazards 
assumption is not violated. Curves in the panel C for AR crosses at very early times and comes 
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close to each other at later time. P for the proportional hazard assumption test based on Schoenfeld 
residuals is 0.0045 for AR. The slight violation of the proportional hazard assumption by AR is 
acceptable. No further stratified analysis by time is conduced.  
C-index for the prognostic model refitting in the test set using 500 bootstrap samples is 
0.6309 (Table 7). The calibration of 1-year, 2-year, 3-year and 5-year survival are presented in 
Figure 6. The mean error for 3- year, 5-year survival is 0.008 and 0.009, respectively. The line 
corrected by 500 bootstrap samples (blue) is close to the diagonal line (grey) in the plot for 3-
year and 5-year survival with 67.45% and 69.57% of AUC, respectively.  
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Figure 5 Kaplan-Meier curves comparing survival across categories of each variable from the final model adjusting for age and the other variables 
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Figure 6 Calibration and ROC curves of 1-year, 2-year, 3-year and 5-year survival for the prognostic model 
in the test set 
37 
Based on the association of OS with the selected clinical and IHC variables, a nomogram 
was generated (Figure 7). To interpret the nomogram, for a HGSOC patient at stage I/II aged 60 
with suboptimal debulking status, positive AR expression, moderate TLR4 expression, no IEL 
CD8 and p16 expression of 1-75% tumor cells, the patient got total task points of  107.5 
(0+50+31+0+2.5+24+0). The estimated possibilities of 3 -year and 5-year survival of this patient 
was 0.7 and 0.54, respectively.  
 






The prognostic model includes age at diagnosis, stage, debulking status, AR, TLR4, CD8+ 
and p16. CD+8 shows a strong dose-response relationship with the survival of HGSOC patients. 
The C-index of the final CoxPHR model fit in the test set is 0.6309, which indicates a fair model. 
Even with the fair predictive power of the final model, the study proposes a novel approach to 
identify the important prognostic factors, which provides a potential opportunity to help clinical 
decision-making and extend the survival of HGSOC patients. 
The nomogram containing selected IHC biomarkers helps HGSCO patients and the 
physicians calculate the possibility of survival and understand the disease visually. The accuracy 
of the prognostic model for 3-year and 5-year survival is 67.45% and 69.57%.  The results should 
be discussed with the physicians to help patients understand the context. The nomogram is based 
on numbers of patients with HGSOC, and it cannot predict how long a particular patient will live.  
4.2 Comparison with previous studies and potential biologic mechanism  
Previous studies are published to estimate the association of individual IHC biomarker and 
HGSOC survival. However, there is no study building a prediction model for HGSOC survival by 
selecting prognostic factors from clinical variables and 9 IHC biomarkers. 
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AR activation  plays a role in ovarian carcinogenesis via causing down-regulation of THF-
beta pathway, upregulation of telomerase and epidermal growth factor receptor, increasing of IL-
6, and IL-8 levels and other changes of downstream and upstream regulation (Mizushima & 
Miyamoto, 2019; Zhu et al., 2017). At the same time, AR expression shows a prognostic 
significance of ovarian cancer, especially in serous subtypes (Zhu et al., 2017). One study 
examining the association of AR expression and EOC survival in 154 EOC cases indicates that 
higher AR expression is a favorable prognostic factor (Nodin et al., 2010). Martins et al. using 
TCGA RNA-sequencing data also revealed that low AR expression is associated with shorter OS 
(F. C. Martins et al., 2014). The conclusion is consistent with the result of HGSOC survival from 
the current study, although the result does not reach statistical significance (AR positive vs AR 
negative HR 0.92, 95% CI 0.81-1.04, P=0.166). It is possible that AR expression affects HGSOC 
survival via involving in response to chemotherapy, but the mechanism is still unclear (Elattar et 
al., 2012; Sun, Huang, Lu, Chang, & Chao, 2015).  
Although in the current analysis, there is no linear trend of TLR4 on HGSOC survival, 
moderate/strong TLR4 expression is associated with longer survival compared to negative/weak 
expression TLR4 expression (Figure 7). The OTTA study reveals that higher TLR4 expression is 
associated with longer survival in low-grade serous ovarian cancer, but no associated with HGSOC 
(Block et al., 2018). Even though the association of TLR4 expression and HGSOC does not reach 
statistical significance, TLR4 expression is still an important factor in the prognostic model. 
Studies show that positive TLR4 is correlated with platinum-sensitive patients (d'Adhemar et al., 
2014; Luo, He, & Wang, 2015), thereby associating with longer OS of ovarian cancer. TLRs plays 
a crucial role in establishing innate immunity (Takeda & Akira, 2005). The TLR4 signaling 
pathway can be MyD88-dependent and MyD88-independent. The TIR domain-containing 
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adaptors, TRIF and TRAM are essential in the MyD88- independent TLR4 pathway. Activation 
of IRF-3 and NF-κB also participates in the pathway (Takeda & Akira, 2005). Some studies link 
MyD88-dependent TLR4 signaling pathways to chemoresistance in EOC (Kelly et al., 2006), and 
MyD88 expression to  HGSOC survival (Block et al., 2018). While in the current study, only TLR4 
is selected to build the prognostic model for HGSOC survival. It suggests that MyD88-independent 
TLR4 signaling pathways might play a crucial role in chemoresistance and affect HGSOC 
survival.  
The biomarker of CD8+ TILs is selected in the prognostic model. CD8+ TILs density 
shows a highly significant dose-response association with HGSCOS survival. The result confirms 
the conclusion indicated by previous studies that CD8+ TILs density is a favorable prognostic 
factor for HGSCOS patients (Ovarian Tumor Tissue Analysis et al., 2017; Pinto et al., 2018; Sato 
et al., 2005). CD8+ TILs produce cytokines, such as tumor necrosis factor (TNF) and interferon- 
γ (IFN-γ), and enzymes, such as granzyme-B and perforin, to eliminate the targeted cells during 
the process of tumorigenesis. The immune response of CD8+ TILs interacts with other immune 
molecules, such as CD27 and MHC-II, affects clinical outcomes in ovarian cancer (Turner, 
Buchsbaum, Straughn, Randall, & Arend, 2016).  
The biomarker p16 is considered a tumor suppressor (Lukas et al., 1995; Romagosa et al., 
2011). Absence and overexpression of p16 are both abnormal. In the nomogram (Figure 7), the 
risk point of >75% of tumor cells nuclei positive weights over the risk point of <1% of tumor cells, 
but both are higher than the risk point of 1-75% of tumor cells nuclei positive. The eukaryotic cell 
cycle composes of four discrete phases, M, G1, S and G2. The G1 phase is the interval between 
mitosis and initiation of DNA replication (Cooper, 2000). p16, as a negative cell cycle regulator, 
acts in the late G1 phase to regulate the transition to the S phase (Kamb & McCormack, 2001). 
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Many studies show that p16 is downregulated in cancer (Fukushima et al., 2002; Guida et al., 2009; 
Moore et al., 2001). While p16 overexpression is also observed in some types of cancer, especially 
human papillomavirus (HPV) related cancer (Klaes et al., 2001; Mulvany, Allen, & Wilson, 2008; 
Volgareva et al., 2004). The overexpressing level of p16, as a prognostic marker, is various for 
different types of cancer. In breast cancer, p16 in 25% of the tumors is associated with unfavorable 
prognosis (Milde-Langosch, Bamberger, Rieck, Kelp, & Löning, 2001). In the current study, the 
overexpression of p16 is defined as over 75% of tumor cells nuclei positive. It is one of the 
predictors in the prognostic model but does not reach statistical significance on HGSOC survival 
compared to <1% and 1%-75% of tumor cells nuclei positive. 
4.3 Limitations 
Ideally, the quantitative IHC score should be used in the prognostic model (Galon et al., 
2012). However, such data cannot be obtained. For the different IHC biomarkers, different score 
systems are used to keep the ordinal variables with as many levels as possible. AR is the only 
dichotomous variable. ER, PR and p16 use a 3-tiered system. TLR4, MyD88, PTEN and CD8+ 
use a 4-tiered system. FOLR1 uses a 6-tiered system. The other issue related to IHC scores is that 
the inter-observer agreement for HGSOC subset from OTTA is not obtained. The studies using 
available IHC data of all histologic subtypes of ovarian cancer from OTTA indicate that 2-score 
system has a higher inter-observer agreement for MyD88, TLR4 and CD8+ (Block et al., 2018; 
Ovarian Tumor Tissue Analysis et al., 2017). The OTTA study estimating the association of 
FOLR1 and ovarian cancer survival indicates a 5-tiered system, combing “absent” and “weak” 
together, is as high as 0.9 in a subset of 183 patients (Köbel et al., 2014). 
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The other limitation of the current study is that glmnet package cannot select ordinal 
variables with all levels together. However, the internal validation, C-index, of the model fitted by 
the selected levels only is not different from that of the model fitted by the selected predictors with 
all levels (0.6922 vs 0.6863). Due to the shortcoming of the package itself, no interaction term is 
added in the CoxPHR model with lasso penalty to improve the interpretability of variable selection. 
The gglasso package was designed by Yang, et al to solve group-lass learning problems (Yang & 
Zou, 2015). Categorical variables with more than two levels can be selected in the model using 
this package. In the current study using glmnet package, the dummy variables were selected first 
and then the dummy variables with other dummy variables grouped in the categorical variable 
were refitted in the model. However, the gglasso package cannot by applied to CoxPHR.  
The missing pattern of IHC biomarkers causes the discrepancy in the sample sizes of the 
training set and the test set. The IHC biomarkers were selected using the training set with all 9 
biomarkers. Compared to the training set, the test set has more HGSOC in stage III/IV and the 
median OS is much shorter. To explore whether the availability of markers affecting the overall 
survival through stage, the relationships between availability of each IHC biomarkers and stage 
are estimated (Table 8).  The absolute Cramér's V values ranged from 0.025 to 0.13, indicating 
weak relationship of availability of each IHC biomarkers and stage. Thus, the conflicting 
prediction power of the prognostic model in the training set and in the test set is not due to the 
availability of each IHC biomarkers. The missing pattern of IHC biomarkers affects the variable 
selection slightly.  
Table 8 Cramér's V of availiablity of each IHC biomarkers and stage 
 AR ER PR TLR4 MyD88 FOLR1 PTEN CD8 p16 
Stage -0.026 0.13 0.039 0.037 0.067 0.075 0.046 0.025 0.042 
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Other covariates that might be related to some IHC biomarkers and HGSOC survival are 
not included in the variable selection due to the inaccessibility of the data. As mentioned before, 
the CA-125 level is a prognostic factor for ovarian cancer survival. The types of treatment might 
be associated with ovarian cancer survival. Patients with stage III/IV ovarian cancer who received 
neoadjuvant chemotherapy (NACT) but not followed by debulking surgery have worse OS 
compared to women with NACT and debulking surgery (Y. L. Liu et al., 2020). A meta-analysis 
including 15 cohort studies indicates that early initiation of chemotherapy is associated with longer 
OS of ovarian cancer patients (Y. Liu et al., 2017). A complete response to chemotherapy after 
NACT improves OS in HGSOC patients (Cohen et al., 2019; Santoro et al., 2019). Previous studies 
also reveal that BRCA1/2 mutations are associated with long-term survival among all ovarian 
cancer cases and HGSOC cases (Chetrit et al., 2008; Huang, 2018; S. I. Kim et al., 2019). However, 
in the training set, only 2 cases have data on BRACA1/2 mutation status. Thus, BRACA1/2 
mutation status is also not included in the current analysis. 
Other potential IHC candidates for HGSOC prognosis need to be evaluated. CD3+ and 
CD4+ TILs indicating the immune response against cancer cells are found to associate with OS in 
many tumor types, such as breast cancer, colon cancer and cervical cancer (Ancuta et al., 2009; 
Hadrup, Donia, & Thor Straten, 2013; Nedergaard, Ladekarl, Thomsen, Nyengaard, & Nielsen, 
2007; Rathore et al., 2014). CD20+ B lymphocytes is associated with a favourable prognosis in 
lung cancer and gastric cancer (Al-Shibli et al., 2008; Hennequin et al., 2016). Adding IHC 
variables related to ovarian cancer and other cancer in the step of variable selection might increase 
the accuracy of the final prognostic model and help identify new prognostic biomarkers for 
HGSOC.  
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4.4 Conclusion and future study 
The final prognostic model indicates that the four IHC biomarkers, AR, TLR4, CD8+ and 
p16, play more crucial roles in the prognosis of HGSOC than the other IHC biomarkers, ER, PR, 
MyD88, FOLR1 and PTEN based on a statistical algorithm. The potential biologic mechanism 
needs to be investigated to explain why AR, TLR4, CD8+ and p16 weights over ER, PR, MyD88, 
FOLR1 and PTEN to predict HGSOC survival. Based on the limitations future studies are 
recommended treating the IHC biomarkers as continuous values and considering other IHC 
candidates and clinical variables, such as adjuvant chemotherapy or not, chemotherapy response, 
pre-treatment and post-treatment CA125 level, BRCA1 and BRCA2 status, as well as other. 
The glmnet package with its vignette is an easy-to-use and efficient package when 
conducting lasso and elastic-net regularized regression. However, it cannot achieve a model with 
grouped lasso penalty, and cannot deal with ordinal predictors.  Although cross-validation is built 
in the package to select the tuning parameters, external validation still needs to be conducted by 
refitting the model and using other packages. A comprehensive R package fitting different types 
of survival and predictor data in regularized CoxPHR analysis should be developed.  
45 
Appendix A Characteristics of ovarian cancer studies included in the current analysis 
Appendix Table 1 Characteristics of 17 Ovarian Cancer Studies from the Ovarian Tumor Tissue Analysis 
(OTTA) consortium 
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